Zimmer Biomet Holdings, Inc. (ZBH) KPIs and segments
Close on Nov 18, 2026Market cap $19.71BP/E 25.1Yield 0.93%
KPI & bộ phận
Chỉ số vận hành và bộ phận làm nên hoạt động của Zimmer Biomet · năm tài chính kết thúc ngày 31 tháng 12
Nhìn nhanh KPI của Zimmer Biomet: 42 chỉ số vận hành, trong đó có Product Sales Volume & Mix Growth Effect, Global Average Selling Price Effect và Consolidated Constant-Currency Net Sales Growth, lấy từ 227 tài liệu nguồn, cùng doanh thu theo bộ phận, sản phẩm và khu vực từ hồ sơ SEC. Mỗi số đều dẫn tới tài liệu gốc. Tất cả chỉ số hiện cả bảng; Cốt lõi chỉ giữ bộ phận và KPI nổi bật. Bảng bộ phận còn có cách xem lũy kế 12 tháng.
Biểu đồ đang trống. Tick vào ô cạnh bất kỳ chỉ số nào ở bảng dưới để vẽ — tick nhiều chỉ số để so sánh trên cùng một biểu đồ.
Bộ phận, KPI nổi bật và mọi chỉ số vận hành từ hồ sơ, thông cáo kết quả và bản trình bày.
| Thêm vào biểu đồ | Chỉ số | Q3 2026 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Knees($M) | 829 | 829 | 911 | 792 | 826 | 793 | 839 | 745 | 801 | 788 | 798 | ||
S.E.T($M) | 586 | 562 | 588 | 542 | 551 | 471 | 489 | 454 | 470 | 453 | 453 | ||
Hips($M) | 563 | 524 | 555 | 506 | 536 | 496 | 520 | 482 | 507 | 491 | 505 | ||
Technology & Data, Bone Cement and Surgical($M) | 199 | 172 | 190 | 161 | 165 | 150 | 175 | 143 | 165 | 157 | |||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
Americas($M) | 1,359 | 1,325 | 1,413 | 1,254 | 1,287 | 1,207 | 1,273 | 1,136 | 1,199 | 1,187 | 1,213 | ||
United States($M) | 1,240 | 1,209 | 1,313 | 1,164 | 1,174 | 1,114 | 1,181 | 1,052 | 1,106 | 1,099 | 1,128 | ||
International($M) | 937 | 877 | 837 | 904 | 796 | 842 | 772 | 836 | 790 | 812 | |||
EMEA($M) | 479 | 490 | 501 | 417 | 458 | 442 | 438 | 376 | 432 | 445 | 426 | ||
Asia Pacific($M) | 340 | 272 | 329 | 331 | 332 | 261 | 313 | 312 | 310 | 258 | 301 | ||
Americas($M) | 546 | 529 | 723 | 647 | 536 | 509 | 695 | 605 | 637 | 639 | 665 | ||
EMEA($M) | 151 | 152 | 166 | 122 | 154 | 151 | 164 | 124 | 152 | 155 | 163 | ||
Asia Pacific($M) | 104 | 93 | 117 | 117 | 120 | 88.8 | 122 | 123 | 122 | 94.4 | 119 | ||
Kỳ báo cáo trước đây (báo cáo lần cuối 2024)1 | |||||||||||||
Americas($M) | 1,050 | 1,027 | 1,098 | 983 | 994 | 939 | 1,010 | 901 | 951 | 950 | |||
EMEA($M) | 296 | 304 | 314 | 257 | 292 | 276 | 287 | 244 | 282 | 290 | |||
Asia Pacific($M) | 215 | 184 | 210 | 215 | 215 | 177 | 210 | 214 | 211 | 183 | |||
Product Sales Volume & Mix Growth Effect(%)1 | 4.4% | 5.5% | 7.2% | 8.4% | 5.2% | 2.2% | 3.4% | 4.8% | 4.2% | ||||
Paragon 28 Acquisition Volume Contribution — Consolidated (Legacy through FY2026Q2)(%)3 | 0.7% | 3.9% | 3.8% | 3.6% | 2.6% | ||||||||
Paragon 28 Acquisition Contribution — S.E.T. Category (Legacy through FY2026Q2)(%) | 2.8% | 15.8% | 15.8% | 14.6% | 11.1% | ||||||||
Paragon 28 Acquisition Contribution — United States (Legacy through FY2026Q2)(%) | 1.0% | 5.4% | 5.4% | 5.0% | 3.8% | ||||||||
Paragon 28 Acquisition Contribution — International (Legacy through FY2026Q2)(%) | 0.4% | 1.7% | 1.6% | 1.7% | 1.2% | ||||||||
Global Average Selling Price Effect(%)1 | -0.7% | -0.8% | -0.4% | 0.2% | 0.2% | 0.1% | 0.7% | 0.8% | 0.2% | ||||
Consolidated Pricing Impact (Earnings Call Commentary)(bps) | -70 | -80 | -40 | -50 | |||||||||
Consolidated Constant-Currency Net Sales Growth(%)8 | 3.7% | 4.7% | 6.8% | 9.2% | 8.6% | 5.4% | 2.3% | 4.9% | 4.1% | 5.6% | 4.4% | 6.1% | |
Knees — Worldwide Constant-Currency Growth(%)2 | -2.6% | 0.1% | 1.8% | 6.9% | 5.3% | 1.8% | 1.9% | 5.6% | 5.5% | 5.5% | 4.3% | 5.6% | |
Knees — United States Constant-Currency Growth(%) | -2.0% | 1.4% | 2.2% | 6.0% | 3.5% | 1.7% | 0.2% | 3.9% | 2.9% | 0.8% | 2.2% | 5.4% | |
Knees — International Constant-Currency Growth(%) | -3.4% | -1.5% | 1.3% | 8.2% | 7.8% | 1.8% | 4.2% | 8.0% | 9.2% | 11.5% | 7.3% | 5.8% | |
Hips — Worldwide Constant-Currency Growth(%)2 | 7.0% | 5.1% | 3.2% | 4.9% | 3.8% | 4.0% | 2.4% | 4.0% | 3.7% | 2.8% | 1.5% | 3.6% | |
Hips — United States Constant-Currency Growth(%) | 5.8% | 5.9% | 5.0% | 7.9% | 4.0% | 5.2% | 3.7% | 3.2% | 4.9% | 1.8% | 1.0% | 4.0% | |
Hips — International Constant-Currency Growth(%) | 8.2% | 4.2% | 1.0% | 1.6% | 3.6% | 2.7% | 1.0% | 4.8% | 2.4% | 3.7% | 2.0% | 3.2% | |
S.E.T. (Sports Medicine, Extremities, Trauma, CMFT) — Constant-Currency Growth(%) | 7.1% | 6.2% | 17.4% | 18.7% | 18.2% | 16.0% | 4.9% | 8.4% | 7.3% | 7.3% | 5.3% | 6.4% | |
Technology & Data, Bone Cement and Surgical — Constant-Currency Growth(%)1 | 13.0% | 21.5% | 11.7% | 6.6% | 11.3% | -2.2% | -3.5% | -4.3% | |||||
Other Category — Constant-Currency Growth (Legacy through FY2024Q3)(%) | -9.5% | 11.3% | 12.2% | 15.9% | |||||||||
United States — Constant-Currency Net Sales Growth(%) | 3.6% | 5.6% | 8.6% | 11.1% | 10.6% | 6.1% | 1.3% | 4.7% | 2.0% | 3.5% | 3.7% | 4.4% | |
International — Constant-Currency Net Sales Growth(%) | 3.9% | 3.5% | 4.2% | 6.6% | 5.9% | 4.6% | 3.7% | 5.2% | 7.1% | 8.5% | 5.4% | 8.7% | |
Organic Constant-Currency Net Sales Growth (Ex-Paragon 28, Legacy through FY2026Q2)(%)3 | 4.0% | 2.9% | 5.4% | 5.0% | 2.8% | ||||||||
Foreign Currency Exchange Rate Impact on Net Sales(%)5 | -0.6% | 0.1% | 2.5% | 1.7% | 1.1% | 1.6% | -1.2% | -0.6% | -0.1% | -1.7% | -1.2% | 0.2% | |
International — Foreign Exchange Impact(%) | -1.5% | 0.2% | 6.1% | 4.0% | 2.6% | 3.5% | -3.0% | -1.5% | -0.2% | -4.1% | -2.9% | 0.4% | |
Knees — Foreign Exchange Impact(%) | -0.5% | 0.3% | 2.7% | 1.7% | 1.0% | 1.3% | -1.3% | -0.5% | -1.6% | -0.9% | 0.3% | ||
Hips — Foreign Exchange Impact(%) | -1.0% | -0.1% | 2.5% | 1.9% | 1.3% | 1.8% | -1.5% | -1.0% | -0.2% | -2.4% | -1.8% | -0.3% | |
S.E.T. — Foreign Exchange Impact(%) | -0.3% | 0.2% | 2.1% | 1.4% | 1.0% | 1.3% | -1.0% | -0.4% | -1.2% | -0.9% | 0.5% | ||
Technology & Data, Bone Cement and Surgical — Foreign Exchange Impact(%) | -1.1% | -0.4% | 2.9% | 2.1% | 1.2% | 2.0% | -1.2% | -0.6% | |||||
Deployed Surgical Instruments Fleet — Gross Carrying Value($M)6 | 4,133 | 4,029 | 3,965 | 3,905 | 3,894 | 3,834 | 3,665 | 3,590 | 3,748 | 3,666 | 3,815 | 3,749 | |
Buildings, Machinery & Manufacturing Equipment — Gross($M) | 2,487 | 2,450 | 2,429 | 2,420 | 2,421 | 2,411 | 2,303 | 2,273 | 2,308 | 2,264 | 2,254 | 2,246 | |
Capitalized Computer Software — Gross($M) | 632 | 620 | 631 | 624 | 612 | 606 | 578 | 575 | 578 | 560 | 555 | 552 | |
Construction in Progress($M) | 328 | 298 | 258 | 286 | 273 | 272 | 259 | 234 | 242 | 236 | 206 | 201 | |
Land($M) | 22.5 | 22.5 | 22.5 | 22.5 | 22.5 | 22.6 | 18.6 | 18.5 | 19 | 18.8 | 18.8 | 18.9 | |
Total Property, Plant & Equipment (Including Instruments) — Gross($M) | 7,602 | 7,419 | 7,305 | 7,257 | 7,222 | 7,146 | 6,823 | 6,690 | 6,896 | 6,745 | 6,849 | 6,766 | |
Accumulated Depreciation (Instruments & Other PP&E)($M) | 5,292 | 5,182 | 5,093 | 5,050 | 5,028 | 4,970 | 4,759 | 4,641 | 4,789 | 4,642 | 4,758 | 4,706 | |
Surgical Instrument Capital Additions($M)2 | 112 | 85.4 | 77.2 | 74.3 | 86 | 80.5 | 59.7 | 51.9 | 41.2 | 65.2 | 82 | 79 | |
Other Property, Plant & Equipment Capital Additions($M) | 75.8 | 54.2 | 36.3 | 74.8 | 55.1 | 50 | 44.6 | 51.5 | 44.5 | 52.7 | 55.1 | 62.9 | |
Additions to Other Intangible Assets($M) | 25 | 62.2 | 39 | 10 | 10 | 30 | 2.40 | 33.4 | 22.3 | 54 | 43.3 | 5 | |
Share Repurchases — Common Shares Purchased2 | 821,128 | 2,917,831 | 2,617,159 | 2,711,242 | 2,160,308 | 554,874 | 5,468,000 | 888,000 | 722,754 | 3,770,867 | |||
Average Price Paid per Repurchased Share($) | 95.54 | 84.60 | 95.52 | 92.21 | 106 | 105 | 109 | 107 | 122 | 116 | |||
Remaining Share Repurchase Authorization($M) | 925 | 1,003 | 1,250 | 770 | 1,020 | 1,250 | 1,308 | 1,905 | 67.8 | 156 | |||
United States Net Sales($M)3 | 1,206 | 1,240 | 1,209 | 1,313 | 1,164 | 1,174 | 1,114 | 1,181 | 1,052 | 1,106 | 1,099 | 1,128 | |
Knees — United States Net Sales($M) | 431 | 455 | 469 | 520 | 440 | 449 | 459 | 490 | 425 | 441 | 458 | 472 | |
Hips — United States Net Sales($M) | 280 | 289 | 278 | 293 | 265 | 273 | 264 | 272 | 255 | 259 | 255 | 263 | |
United States — Reported Net Sales Growth(%)2 | 3.6% | 5.6% | 8.6% | 11.1% | 10.6% | 6.1% | 1.3% | 4.7% | 2.0% | 3.5% | 3.7% | 4.4% | |
Knees — United States Reported Growth(%) | -2.0% | 1.4% | 2.2% | 6.0% | 3.5% | 1.7% | 0.2% | 3.9% | 2.9% | 0.8% | 2.2% | 5.4% | |
Hips — United States Reported Growth(%) | 5.8% | 5.9% | 5.0% | 7.9% | 4.0% | 5.2% | 3.7% | 3.2% | 4.9% | 1.8% | 1.0% | 4.0% | |
International Net Sales($M)3 | 857 | 937 | 877 | 931 | 837 | 904 | 796 | 842 | 772 | 836 | 790 | 812 | |
Knees — International Net Sales($M) | 336 | 374 | 359 | 391 | 352 | 377 | 334 | 349 | 320 | 360 | 330 | 327 | |
Hips — International Net Sales($M) | 256 | 274 | 247 | 262 | 242 | 264 | 232 | 248 | 227 | 248 | 236 | 242 | |
International — Reported Net Sales Growth(%)2 | 2.4% | 3.7% | 10.3% | 10.6% | 8.5% | 8.1% | 0.7% | 3.7% | 6.9% | 4.4% | 2.5% | 9.1% | |
Knees — International Reported Growth(%) | -4.5% | -0.9% | 7.6% | 12.1% | 10.2% | 4.8% | 1.2% | 6.8% | 9.1% | 7.8% | 5.0% | 6.7% | |
Hips — International Reported Growth(%) | 6.2% | 4.0% | 6.5% | 5.6% | 6.4% | 6.5% | -2.0% | 2.8% | 1.9% | -1.0% | -1.7% | 2.5% | |
Americas — Operating Profit Margin (Q1 2026 CODM Recast Basis)(%)5 | 37.9% | 40.2% | 40.0% | 41.2% | 41.6% | 42.1% | |||||||
Americas — Operating Profit Margin (As-Originally-Reported MD&A Basis)(%) | 37.9% | 40.2% | 40.0% | 51.6% | 51.2% | 51.8% | 53.3% | 53.9% | |||||
Americas — Segment Cost of Products Sold($M) | 296 | 309 | 298 | 278 | 284 | 293 | 268 | 263 | 235 | 249 | 237 | ||
Americas — Segment Research & Development Expense($M) | 75.9 | 71.1 | 71.9 | -215 | 73.7 | 73.6 | 71.1 | 0.90 | 0.80 | 0.60 | 1.20 | ||
Americas — Segment Selling, General & Administrative Expense($M) | 447 | 433 | 426 | 230 | 388 | 385 | 360 | 314 | 295 | 313 | 309 | ||
Americas — Segment Depreciation & Amortization($M) | 46.5 | 45.1 | 44.9 | 27.7 | 46 | 45.8 | 40.7 | 38.5 | 38.3 | 37.1 | 36.5 | ||
EMEA — Operating Profit Margin (Q1 2026 CODM Recast Basis)(%)5 | 29.7% | 31.6% | 31.1% | 28.9% | 33.6% | 34.1% | |||||||
EMEA — Operating Profit Margin (As-Originally-Reported MD&A Basis)(%) | 29.7% | 31.6% | 31.1% | 29.2% | 33.9% | 33.5% | 32.3% | 34.4% | |||||
EMEA — Segment Cost of Products Sold($M) | 163 | 183 | 186 | 196 | 157 | 167 | 166 | 151 | 133 | 151 | 155 | ||
EMEA — Segment Research & Development Expense($M) | 1.90 | 1.90 | 1.70 | 4.90 | 1.80 | 1.70 | 2.10 | 2.60 | 2.40 | 2 | 2 | ||
EMEA — Segment Selling, General & Administrative Expense($M) | 130 | 143 | 150 | 147 | 132 | 136 | 123 | 120 | 118 | 128 | 133 | ||
EMEA — Segment Depreciation & Amortization($M) | 17.1 | 16.8 | 16.5 | 18.5 | 16.4 | 15.9 | 15.6 | 15.9 | 16.3 | 16.9 | 16.8 | ||
Asia Pacific — Operating Profit Margin (Q1 2026 CODM Recast Basis)(%)5 | 36.3% | 30.7% | 34.2% | 34.5% | 36.2% | 34.1% | |||||||
Asia Pacific — Operating Profit Margin (As-Originally-Reported MD&A Basis)(%) | 36.3% | 30.7% | 34.2% | 35.2% | 36.6% | 34.1% | 39.2% | 36.2% | |||||
Asia Pacific — Segment Cost of Products Sold($M) | 116 | 124 | 88 | 122 | 115 | 118 | 83.3 | 103 | 98 | 99.7 | 75.1 | ||
Asia Pacific — Segment Research & Development Expense($M) | 2.70 | 3.90 | 3.30 | 4 | 3.30 | 3.50 | 3.30 | 3.30 | 3.40 | 3.30 | 3.30 | ||
Asia Pacific — Segment Selling, General & Administrative Expense($M) | 88.9 | 107 | 88 | 90 | 94.3 | 90.7 | 85.1 | 84.5 | 87.2 | 85.1 | 85.2 | ||
Asia Pacific — Segment Depreciation & Amortization($M) | 16.3 | 15.7 | 15.3 | 15.8 | 15.2 | 15 | 15.2 | 15.6 | 15 | 15.1 | 15.4 | ||
Total Inventories (Footnote Disaggregation)($M)3 | 2,367 | 2,270 | 2,247 | 2,286 | 2,484 | 2,454 | 2,244 | 2,235 | 2,369 | 2,370 | 2,388 | 2,385 | |
Finished Goods Inventory($M) | 1,900 | 1,808 | 1,779 | 1,832 | 2,011 | 1,968 | 1,757 | 1,772 | 1,872 | 1,855 | 1,847 | 1,831 | |
Work in Process Inventory($M) | 180 | 176 | 182 | 181 | 198 | 208 | 215 | 175 | 189 | 216 | 227 | 247 | |
Raw Materials Inventory($M) | 288 | 287 | 286 | 273 | 275 | 278 | 272 | 289 | 308 | 299 | 315 | 308 | |
Product Liability & Litigation Reserve($M)4 | 139 | 138 | 133 | 136 | 147 | 157 | 135 | 156 | 155 | 208 | 227 | 244 | |
Quality & Litigation-Related Charges($M) | 17.8 | 17.8 | 5 | 12.3 | 3.10 | 5.30 | 2.10 | 22.2 | 3.80 | 3.40 | 1 | 17.8 | |
Restructuring & Cost Transformation Charges($M) | 14.4 | 29.8 | 6.30 | 106 | 21.4 | 17.5 | 36 | 20.9 | 32.2 | 41.5 | 124 | 61.3 | |
2025 Restructuring Program Accrued Liability($M) | 35.8 | 49.5 | 68.8 | 99.6 | 16.9 | 11.4 | 13.1 | ||||||
Acquisition, Integration, Licensing & Other Charges($M) | 19.6 | 18.1 | 15.6 | 21.9 | -34.4 | 78.9 | 10.6 | 13.7 | 4.40 | 5.20 | 0.40 | 5.30 | |
Free Cash Flow (Non-GAAP)($M)1 | 372 | 308 | 246 | 368 | 278 | 248 | 279 | 403 | 310 | 252 | 90.9 | 447 | |
Net Debt (Non-GAAP)($M) | 7,104 | 7,069 | 7,047 | 6,927 | 6,820 | 7,016 | 5,792 | 5,679 | 5,882 | 5,415 | 5,403 | 5,352 | |
Adjusted Gross Margin (Non-GAAP)(%)3 | 71.7% | 71.1% | 73.0% | 72.4% | 72.6% | 72.3% | 71.5% | 71.3% | 71.0% | 71.6% | 72.9% | 72.5% | |
GAAP Gross Margin (Earnings Release Reconciliation)(%) | 63.1% | 63.3% | 64.6% | 56.8% | 63.2% | 63.8% | 63.3% | 63.2% | 62.4% | 64.1% | 65.4% | 64.8% | |
Adjusted Gross Profit (Non-GAAP)($M) | 1,480 | 1,548 | 1,524 | 1,624 | 1,453 | 1,502 | 1,366 | 1,443 | 1,295 | 1,391 | 1,378 | 1,406 | |
Cost of Products Sold (% of Net Sales — MD&A)(%) | 28.8% | 29.2% | 27.6% | 27.9% | 28.5% | 28.8% | 29.5% | 28.5% | 27.1% | ||||
Adjusted Operating Profit Margin (Non-GAAP)(%)5 | 25.1% | 25.7% | 27.3% | 29.1% | 26.5% | 27.8% | 26.2% | 30.8% | 26.3% | 28.5% | 28.6% | 30.3% | |
GAAP Operating Profit Margin(%) | 14.9% | 15.0% | 17.9% | 6.9% | 17.6% | 14.4% | 15.3% | 19.2% | 15.3% | 18.1% | 14.1% | 18.3% | |
Adjusted Operating Profit (Non-GAAP)($M) | 519 | 560 | 571 | 653 | 531 | 579 | 501 | 623 | 480 | 553 | 539 | 589 | |
Research & Development (% of Net Sales — MD&A)(%) | 5.1% | 4.8% | 5.0% | 5.8% | 5.5% | 5.8% | 6.1% | 5.6% | 5.7% | ||||
Selling, General & Administrative (% of Net Sales — MD&A)(%) | 41.4% | 41.3% | 40.7% | 40.5% | 39.2% | 39.7% | 38.9% | 38.0% | 39.0% | ||||
Intangible Assets Amortization (% of Net Sales — MD&A)(%) | 8.0% | 7.5% | 7.8% | 8.8% | 7.7% | 7.9% | 8.1% | 7.4% | 7.5% | ||||
Adjusted Diluted Earnings per Share (Non-GAAP)($)3 | 1.90 | 2.07 | 2.09 | 2.42 | 1.90 | 2.07 | 1.81 | 2.31 | 1.74 | 2.01 | 1.94 | 2.20 | |
Adjusted Net Earnings (Non-GAAP)($M) | 363 | 400 | 409 | 480 | 377 | 411 | 361 | 462 | 353 | 415 | 400 | 458 | |
Adjusted Effective Tax Rate (Non-GAAP)(%) | 17.6% | 18.0% | 18.0% | 17.9% | 17.8% | 18.2% | 18.2% | 17.5% | 17.7% | 18.2% | 18.5% | 15.8% | |
GAAP Effective Tax Rate(%) | 16.2% | 21.8% | 20.9% | -40.7% | 17.2% | 31.7% | 20.3% | 16.9% | -8.2% | 19.6% | 19.7% | -47.6% | |
CEO to Median Employee Pay Ratio (DEF 14A)1 | |||||||||||||
Pre-Tax Share-Based Compensation Expense($M) | 24.2 | 24.6 | 24.2 | 24.1 | 25.3 | 21.2 | 19.6 | 21.1 | 24.5 | 26.4 | 29 | 25.3 | |
Paragon 28 — Worldwide Foot & Ankle Net Revenue (Pre-Acquisition through FY2024Q4)($M) | 71.8 | 62.3 | 61.0 | 61.1 | 60.6 | ||||||||
Paragon 28 — Deployed Surgical Instruments, Gross (Pre-Acquisition through FY2024)2 | |||||||||||||
Paragon 28 — Property & Equipment, Net (Pre-Acquisition through FY2024Q4)($M) | 71.4 | 74.0 | 74.9 | 75.7 | 74.1 | ||||||||
Paragon 28 — Inventories, Net (Pre-Acquisition through FY2024Q4)($M) | 90.0 | 96.5 | 96.4 | 94.6 | 90.1 | ||||||||
Paragon 28 — Gross Profit (Pre-Acquisition through FY2024Q4)($M)4 | 52.3 | 46.2 | 45.8 | 47.2 | 42.4 | ||||||||
Paragon 28 — Research & Development Expense (Pre-Acquisition through FY2024Q4)($M) | 6.74 | 5.66 | 7.08 | 7.58 | 8.10 | ||||||||
Paragon 28 — Selling, General & Administrative Expense (Pre-Acquisition through FY2024Q4)($M) | 52.0 | 49.0 | 49.4 | 54.8 | 48.3 | ||||||||
Paragon 28 — Operating Loss (Pre-Acquisition through FY2024Q4)($M) | -6.44 | -8.45 | -10.8 | -15.1 | -14.0 | ||||||||
Paragon 28 — Operating Cash Flow (Pre-Acquisition through FY2024Q4)($M) | -3.28 | -2.67 | -10.2 | -11.0 | -16.4 | ||||||||
Monogram Technologies — Robotics R&D Expense (Pre-Acquisition through FY2025Q2)($M)5 | 2.26 | 2.26 | 1.74 | 2.21 | 2.43 | 2.41 | 3.01 | ||||||
Monogram Technologies — General & Administrative Expense (Pre-Acquisition through FY2025Q2)($M) | 0.77 | 1.03 | 1.12 | 1.09 | 1.12 | 1.08 | 1.08 | ||||||
Monogram Technologies — Operating Loss (Pre-Acquisition through FY2025Q2)($M) | -3.07 | -3.33 | -2.92 | -5.15 | -3.63 | -3.61 | -3.88 | ||||||
Monogram Technologies — Operating Cash Outflow (Pre-Acquisition through FY2025Q2)($M) | -2.30 | -2.31 | -3 | -4.49 | -2.83 | -3.65 | -3.11 | ||||||
Monogram Technologies — Cash & Cash Equivalents (Pre-Acquisition through FY2025Q2)($M) | 12.8 | 13.3 | 15.7 | 16.6 | 7.31 | 10.1 | 13.6 | ||||||
Monogram Technologies — Total Assets (Pre-Acquisition through FY2025Q2)($M) | 15 | 15.4 | 17.8 | 20.2 | 9.82 | 12.5 | 16.6 | ||||||
FDA 510(k) Premarket Clearances — Zimmer Biomet1 | 4 | 11 | 5 | 2 | 7 | 2 | 3 | 6 | 6 | 5 | 2 | 5 | |
U.S. Orthopedic Industry Total — FDA 510(k) Clearances | 856 | 923 | 756 | 806 | 797 | 886 | 736 | 856 | 767 | 793 | 713 | 877 | |
FDA PMA Premarket Approvals & Supplements — Zimmer Biomet1 | 6 | 3 | 4 | 0 | 3 | 3 | 0 | 4 | 2 | 2 | 2 | 2 | |
U.S. Orthopedic Industry Total — FDA PMA Approvals & Supplements | 565 | 608 | 567 | 525 | 585 | 588 | 524 | 683 | 538 | 550 | 459 | 656 | |
FDA Device Recall Events (openFDA Database) — Zimmer Biomet1 | 7 | 7 | 2 | 22 | 1 | 5 | 5 | 2 | 3 | 24 | 2 | 22 | |
FDA Recall Enforcement Reports — Zimmer Biomet | 13 | 1 | 2 | 23 | 0 | 6 | 4 | 2 | 4 | 23 | 2 | 22 | |
FDA MAUDE Adverse Event Reports — Zimmer Biomet4 | 2,949 | 3,545 | 2,975 | 4,224 | 5,728 | 5,494 | 4,695 | 5,066 | 4,531 | 5,137 | 4,624 | 4,781 | |
FDA MAUDE — Device Malfunction Reports | 1,410 | 1,341 | 1,355 | 1,535 | 1,700 | 1,622 | 1,570 | 1,735 | 1,339 | 1,505 | 1,550 | 1,730 | |
FDA MAUDE — Patient Injury Reports | 1,517 | 2,193 | 1,586 | 2,685 | 4,005 | 3,863 | 3,125 | 3,329 | 3,186 | 3,632 | 3,073 | 3,049 | |
FDA MAUDE — Patient Death Reports | 13 | 11 | 33 | 4 | 23 | 9 | 0 | 0 | 6 | 0 | 1 | 2 | |
U.S. Orthopedic Panel — Total Industry MAUDE Reports | 1,189,695 | 923,529 | 811,618 | 751,012 | 819,444 | 632,296 | 685,251 | 709,498 | 699,798 | 631,546 | 586,309 | 573,619 | |
U.S. Federal Orthopedic Prime Contract Obligations — Zimmer Biomet (USAspending.gov)($M) | 0.86 | 0.28 | 5.11 | 5.07 | 6.58 | 6.63 | 5.46 | 5.61 | 5.80 | 5.83 | 6.62 | 5.57 | |
U.S. Producer Price Index — Surgical Appliance & Supplies Mfg / Orthopedics (NAICS 339113)1 | |||||||||||||
U.S. General Medical & Surgical Hospitals Revenue (Census QSS)($M) | 47,896 | 46,674 | 46,834 | 46,295 | 45,370 | 45,358 | 45,284 | 43,778 | 43,505 | 43,709 | 43,264 | ||
Consolidated Net Sales (GAAP)($M)5 | 2,063 | 2,177 | 2,087 | 2,244 | 2,001 | 2,077 | 1,909 | 2,023 | 1,824 | 1,942 | 1,889 | 1,940 | |
Cost of Products Sold, Excluding Intangible Amortization (GAAP)($M) | 595 | 636 | 576 | 792 | 559 | 592 | 550 | 587 | 539 | 554 | 512 | 539 | |
Research & Development Expense (GAAP)($M) | 106 | 105 | 103 | 119 | 116 | 113 | 111 | 109 | 112 | 109 | 108 | 113 | |
Selling, General & Administrative Expense (GAAP)($M) | 855 | 899 | 850 | 872 | 811 | 815 | 759 | 747 | 710 | 737 | 736 | 722 | |
Operating Profit (GAAP)($M) | 308 | 326 | 373 | 155 | 351 | 300 | 292 | 389 | 280 | 351 | 266 | 354 | |
Net Earnings Attributable to Zimmer Biomet (GAAP)($M) | 192 | 198 | 238 | 139 | 231 | 153 | 182 | 240 | 249 | 243 | 172 | 419 | |
Net Cash Provided by Operating Activities (GAAP)($M)1 | 560 | 448 | 359 | 517 | 419 | 378 | 383 | 506 | 396 | 369 | 228 | 588 | |
Additions to Other Property, Plant & Equipment (GAAP Cash Flow Statement)($M) | 75.8 | 54.2 | 36.3 | 74.8 | 55 | 50.1 | 44.6 | 51.5 | 44.5 | 52.7 | 55.1 | 62.8 | |
Total Assets (GAAP)($M)7 | 23,539 | 22,798 | 22,722 | 23,092 | 23,488 | 22,865 | 22,184 | 21,365 | 21,720 | 21,520 | 21,452 | 21,497 | |
Cash & Cash Equivalents($M) | 400 | 410 | 424 | 592 | 1,293 | 557 | 1,385 | 526 | 569 | 420 | 393 | 416 | |
Inventories (GAAP Balance Sheet)($M) | 2,367 | 2,270 | 2,247 | 2,286 | 2,484 | 2,454 | 2,244 | 2,235 | 2,369 | 2,370 | 2,388 | 2,385 | |
Property, Plant & Equipment, Net (Includes Net Instruments)($M) | 2,310 | 2,237 | 2,212 | 2,207 | 2,194 | 2,176 | 2,065 | 2,049 | 2,107 | 2,103 | 2,091 | 2,060 | |
Goodwill($M) | 10,336 | 9,920 | 9,932 | 9,947 | 9,702 | 9,710 | 8,989 | 8,951 | 8,912 | 8,825 | 8,792 | 8,819 | |
Intangible Assets, Net($M) | 4,635 | 4,462 | 4,548 | 4,717 | 4,740 | 4,891 | 4,468 | 4,598 | 4,665 | 4,707 | 4,734 | 4,856 | |
Long-Term Debt($M) | 6,217 | 6,278 | 6,295 | 6,932 | 7,513 | 6,753 | 6,576 | 5,342 | 4,738 | 3,957 | 4,826 | 4,868 | |
Total Stockholders' Equity($M) | 12,716 | 12,624 | 12,673 | 12,698 | 12,757 | 12,525 | 12,395 | 12,468 | 12,375 | 12,741 | 12,598 | 12,481 | |
52 chỉ số không có số liệu trong 12 quý gần nhất — .
In nghiêng là số StockData tự tính từ số đã báo cáo (rê chuột để xem công thức). Số có gạch chân chấm là số đọc từ câu chữ trong thông cáo kết quả và bản trình bày; rê chuột để xem đúng câu đó. Tick vào một dòng để thêm vào biểu đồ phía trên (tối đa 8 đường).
Phương pháp và các chỉ số bị loại
- Các dòng ở Cốt lõi lấy từ thuyết minh bộ phận và phân tách doanh thu trong hồ sơ 10-K và 10-Q (XBRL), có liên kết tới từng hồ sơ. Số quý 4 bằng cả năm tài chính trừ chín tháng đầu (hiện bằng chữ in nghiêng).
- Core Orthopedic Operational Drivers: Procedure volume and product mix growth effect, global selling price realization (both 10-Q/10-K MD&A % and quarterly earnings call basis points including Q4), management's guided constant-currency net sales growth across Knees, Hips, S.E.T., and Technology & Data, and the $4.13B gross deployed surgical instrument fleet consigned across hospitals and ambulatory surgery centers (ASCs).
- Surgical Instrument Capital Expenditure Distinction: In orthopedic reconstruction, Zimmer Biomet consigns reusable surgical instrument trays to hospitals and ASCs and reports 'Additions to instruments' ($300.5M in FY2025; $111.8M in Q3 2026) on a separate cash flow line from 'Additions to other property, plant and equipment' ($224.5M in FY2025; $75.8M in Q3 2026). Both capital outflows are deducted in Free Cash Flow.
- Q1 2026 Regional Segment Cost-Allocation Recast & Paragon 28 Anniversary: In Q1 2026, Zimmer Biomet moved EMEA/APAC Foot & Ankle results and centralized R&D and global marketing expenses into Americas operating profit, recasting FY2025 quarterly comparatives. Paragon 28 (acquired April 21, 2025) was tracked separately in Organic Constant-Currency Growth through Q2 2026 and became fully organic in Q3 2026.
- Subsidiary & Statutory Filings: Zimmer Biomet files consolidated U.S. GAAP financial statements without standalone parent-company schedules. Pre-acquisition SEC filings of acquired subsidiaries Paragon 28, Inc. (through FY2024Q4) and Monogram Technologies Inc. (through FY2025Q2), along with annual UK statutory Gender Pay Gap filings for Zimmer Biomet's UK operating subsidiaries through FY2025, are presented in dedicated subsidiary groups.
- Derived Period Splits: Only cumulative year-to-date cash flow and XBRL subtractions (YTD − prior YTD for Q2/Q3 and FY − 9M / Q4 = full year − nine months for Q4) are used where quarterly filings report cumulative figures.
Không hiện vì thiếu các kỳ gần đây (14)
- ROSA Surgical Robotics Global Installed Base ('more than 2,000 units') — Disclosed only with lower-bound qualifiers in earnings calls and presentations without exact quarterly installed unit tables.
- Z1 Triple-Taper Hip Stem Share of U.S. Hip Stems ('over 35%' in Q4 2025, 'about 40%' in Q2 2026, 'over 50%' in Q3 2026) — Qualified as bounds in Q4 2025 and Q3 2026.
- Persona OsseoTi Cementless Knee Penetration in the U.S. (~35% in Q4 2025, >50% long-term target) — Point penetration disclosed in only a single recent period.
- Oxford Cementless Partial Knee Market Share ('over 20%') & HAMMR Automated Hip Impactor Share ('nearly 30%') — Disclosed only as bound estimates on earnings calls.
- Active Global Patents & Patent Applications ('over 6,000' / 'more than 6,500') and Countries Served ('more than 25' direct / 'more than 100' distribution) — Disclosed only as lower bounds in Form 10-K.
- Global Employee Headcount in Form 10-K ('approximately 17,000' in FY2025, 'approximately 18,000' in FY2024) — Rounded to nearest thousand in Form 10-K; exact DEF 14A pay-ratio employee counts (17,149 in FY2025, 18,042 in FY2022, 20,122 in FY2020) are determined once every 3 years and therefore non-consecutive.
- Global Female Workforce Share & Director+ Share (Sustainability Reports) — Reported for FY2020–FY2023 (37%–39% workforce) but discontinued in the 2024 and 2025 Sustainability Reports.
- Dental & Spine / ZimVie Pre-Spin-Off Product Categories (FY2016–FY2021) — Discontinued following the March 1, 2022 spin-off of ZimVie Inc.
- Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) › Biomet 3i UK Limited — Mean Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.
- Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) › Biomet 3i UK Limited — Median Bonus Gender Gap (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.
- Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) › Biomet 3i UK Limited — Female Share in Top Pay Quartile (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.
- Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) › Biomet 3i UK Limited — Female Employees Receiving Bonus (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.
- Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) › Biomet 3i UK Limited — Male Employees Receiving Bonus (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.
- Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings › Biomet 3i UK Limited (UK Co. 03230910) — Median Hourly Gender Pay Gap (Legacy Dental Subsidiary through FY2021) — Discontinued or non-continuous in recent periods.
Dữ liệu cập nhật 2026-11-14.
Mỗi KPI một trang riêng
Đầy đủ lịch sử, biểu đồ, nguồn và cách trích dẫn cho từng chỉ số
Procedure Volume/Mix, Selling Price & Constant-Currency Growth Drivers (Key #1)
Deployed Surgical Instruments Fleet & Capital Deployment (Key #2)
U.S. vs. International Implant Mix & Regional Segment Cost Structure
Inventory by Stage, Commercial Reserves, Non-GAAP Profitability & Cash Flow
- Total Inventories (Footnote Disaggregation) ($M)47 kỳ
- Remaining Performance Obligations (Contracted Backlog) ($M)8 kỳ
- Product Liability & Litigation Reserve ($M)21 kỳ
- Free Cash Flow (Non-GAAP) ($M)35 kỳ
- Adjusted Gross Margin (Non-GAAP) (%)38 kỳ
- Adjusted Operating Profit Margin (Non-GAAP) (%)39 kỳ
- Adjusted Diluted Earnings per Share (Non-GAAP) ($)34 kỳ
- Operating Lease Cost (Annual) ($M)9 kỳ
Workforce Safety, Product Quality, Supply Chain & Sustainability
- Global Total Recordable Incident Rate (TRIR) (×)8 kỳ
- Medical Device Single Audit Program (MDSAP) Audits Conducted4 kỳ
- 3TG Conflict Minerals In-Scope Suppliers Surveyed (Form SD)9 kỳ
- Total Scope 1 & 2 Market-Based GHG Emissions (tCO2e)9 kỳ
- Zero Waste to Landfill (ZWTL) Internally Certified Sites4 kỳ
- CEO to Median Employee Pay Ratio (DEF 14A) (×)7 kỳ
Paragon 28, Inc. — Acquired Foot & Ankle Subsidiary (Pre-Acquisition through FY2024Q4)
Monogram Technologies Inc. — Acquired Surgical Robotics Subsidiary (Pre-Acquisition through FY2025Q2)
Zimmer Biomet UK Subsidiaries — Statutory Gender Pay Gap Filings
External Regulatory, Clinical, Federal Procurement & Industry Macro Indicators
- FDA 510(k) Premarket Clearances — Zimmer Biomet154 kỳ
- FDA PMA Premarket Approvals & Supplements — Zimmer Biomet154 kỳ
- FDA Device Recall Events (openFDA Database) — Zimmer Biomet154 kỳ
- FDA MAUDE Adverse Event Reports — Zimmer Biomet154 kỳ
- Sponsored Clinical Trials Started — Zimmer Biomet (ClinicalTrials.gov)11 kỳ
- U.S. Federal Orthopedic Prime Contract Obligations — Zimmer Biomet (USAspending.gov) ($M)118 kỳ
- U.S. Producer Price Index — Surgical Appliance & Supplies Mfg / Orthopedics (NAICS 339113) (×)142 kỳ
Consolidated Financial Context (GAAP)
Tài liệu nguồn mới nhất
Các tài liệu được trích nhiều nhất cho số liệu mới nhất của Zimmer Biomet
- Zimmer Biomet Form 10-Q (FY2026Q3) ↗
- U.S. FDA openFDA Medical Device Clearances, PMA, Recalls & MAUDE ↗
- Zimmer Biomet Form 8-K Earnings Release (FY2026Q3) ↗
- Zimmer Biomet Form 8-K Earnings Release (FY2025Q4) ↗
- Paragon 28 Form 10-K (FY2024) ↗
- Zimmer Biomet 2025 Sustainability Report ↗
- Zimmer Biomet Form 10-K (FY2025) ↗
- Zimmer Biomet Form 10-Q (filed 2026-11-04) ↗
- Zimmer Biomet Form 10-K (filed 2026-02-20) ↗
- USAspending.gov U.S. Federal Orthopedic Contract Awards — Zimmer Biomet ↗
- Zimmer Biomet Form 10-K (FY2024) ↗
- Zimmer Biomet Form SD Conflict Minerals Report (FY2025) ↗
See a number that looks wrong?